Celltrion Expands Brazil Portfolio to 10 Products with New Treatments

Celltrion is expanding its product offerings in Brazil with the introduction of three new treatments for autoimmune and bone diseases, bolstering its presence in one of Latin America's largest pharmaceutical markets. The Brazilian subsidiary of the company recently launched Coivolma, the local brand name for ustekinumab, alongside Stoboclo and Osenvelt, both derived from denosumab.

Coivolma is available in 45 mg and 90 mg prefilled syringes, as well as a 130 mg vial, while Stoboclo comes in a 60 mg prefilled syringe and Osenvelt in a 120 mg vial. The introduction of these formulations and dosages aims to provide local physicians with greater prescribing flexibility and allows Celltrion to cater to a wider range of patient needs.

Coivolma is marketed as Steqeyma in global markets, including the United States, and is approved for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The company chose the Coivolma name specifically for Brazil, considering local linguistic factors. These new launches also mark Celltrion's expansion beyond its existing autoimmune and oncology businesses in Brazil, as the company now sells a total of 10 products in the Brazilian market.

With products like Remsima, Hertrazuma, and Truxima already securing significant market shares in the private pharmaceutical sector, Celltrion plans to leverage its existing commercial infrastructure to accelerate the market entry of these new offerings.

By utilizing its established customer base and sales channels, Celltrion aims to create synergies between its current and newly launched products, generating additional opportunities for prescriptions and sales while strengthening its competitive position in Brazil. The company's expansion in Brazil also broadens its autoimmune treatment lineup, now featuring ustekinumab alongside infliximab, adalimumab, and omalizumab.

Further product launches, including Eydenzelt, an aflibercept-based ophthalmic treatment, and Aptozma, a tocilizumab-based autoimmune treatment, are anticipated by the end of the year. Celltrion's focus will be on supply capabilities, competitive pricing, and product quality as it fortifies its market position in Brazil and continues to diversify its offerings in the region.